Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Br J Dermatol
; 183(2): 265-275, 2020 08.
Article
in En
| MEDLINE
| ID: mdl-31705526
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Fumarates
Type of study:
Clinical_trials
/
Guideline
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
Br J Dermatol
Year:
2020
Document type:
Article
Affiliation country:
Country of publication: